Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Mar 2023
The American College of Rheumatology (ACR) and the American College of Hip Surgery (AAHKS) have released new guidelines.
Read Full NewsThe U.S. Food and Drug Administration has declined to approve Achieve Life Sciences' drug to treat nicotine dependence in adults, citing unresolved issues found at a...
The profession has always attracted perfectionists. Experts worry a more fear-based version of the trait could affect both doctors and patients.
Rucaparib maintenance delays both first and second subsequent therapies among patients with advanced ovarian cancer.
1.
Antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer
2.
Muscle Strength, Fitness Linked to Lower Mortality Risk in Patients With Cancer
3.
Nearly 6 Million Deaths From Five Major Cancer Types Averted Since 1975
4.
'Personalized' Approach to RT for Bladder Cancer Promising but Challenging
5.
Psychedelic Therapy Tied to Reduced Depression, Anxiety.
1.
Biologic Therapies for Cutaneous Immune-Related Adverse Events in the Era of Immune Checkpoint Inhibitors
2.
Fibroma: Understanding the Causes, Symptoms, and Treatment Options
3.
Tumor Ecosystem Modulation in Precision Oncology
4.
A Novel Gemcitabine-Releasing Intravesical System for Intermediate-Risk Non-Muscle-Invasive Bladder Cancer
5.
Gender-Specific Dual Antiplatelet Therapy Strategies for Women After PCI
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
International Lung Cancer Congress®
1.
Should We Use DARA Up Front As First-Line Therapy in MM?
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
3.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
4.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
5.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge